Drug Profile
Research programme: cardiovascular disease therapeutics - Eli Lilly and Company/Zydus Cadila
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Zydus Cadila
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in India
- 16 Apr 2010 Early research in Cardiovascular disorders in India (unspecified route)